PreHevbrio: the first approved 3-antigen hepatitis B vaccine

Area of Science:

• Hepatitis B research
• Vaccine development
• Immunology

Background:

• Hepatitis B remains a significant global health concern, with many adults lacking adequate protection from existing vaccines.
• Current single S-antigen hepatitis B vaccines (1A-HBV) may not provide optimal protection for all adult populations.

Purpose of the Study:

• To review the development of a novel 3-antigen hepatitis B vaccine (3A-HBV).
• To summarize Phase 3 clinical trial data on the immunogenicity and safety of 3A-HBV in adults.

Main Methods:

• Review of the development and clinical trial data for 3A-HBV.
• Analysis of immunogenicity and safety outcomes in adult participants.

Main Results:

• 3A-HBV demonstrated high immunogenicity across all adult age groups, including older adults.
• The vaccine showed superior seroprotection rates compared to 1A-HBV, offering faster and more durable protection.
• Favorable safety profile observed in Phase 3 trials.

Conclusions:

• 3A-HBV is a highly immunogenic and safe option for hepatitis B prevention in adults.
• It provides enhanced protection, particularly for populations that respond poorly to conventional vaccines.
• The vaccine offers a valuable new tool for combating hepatitis B infection in adults.